5 billion people have access to medicine
2 billion to go

The Access to Medicine Foundation stimulates and guides pharmaceutical companies to do more for the people living in low- and middle-income countries without access to medicine.

Quick access

Our research programmes

Access to
Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Visit this programme

Antimicrobial
Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Visit this programme

Access to
Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.

Visit this programme

View all news

Event - 09 Mar 2021

Goldman Sachs to co-host investor launches of the 2021 Access to Medicine Index

Goldman Sachs and the Access to Medicine Foundation will co-host a series of investor launch events on the 2021 Access to Medicine Index, bringing together investor and company representatives from Europe, USA and Japan.

View upcoming events

Publication - 25 Mar 2021

Closing gaps in access to medicine for children: how R&D and delivery efforts can be ramped up

With significant gaps in paediatric treatment options, this analysis takes a deep dive into the actions of 20 of the world’s largest pharma companies to develop and deliver much-needed medicines for children.

View all publications

What leaders say

"The Access to Medicine Index is a very important project. What gets measured, gets done."

Dr. Margaret Chan

Former Director General, World Health Organisation

"I’ve been impressed by the Access to Medicine Index. It presents well-balanced stakeholder views on good practices for the pharmaceutical industry and it provides clear standards against which the performance of individual companies can be judged."

Mary Robinson

President, Realizing Rights, Former UN High Commissioner for Human Rights (1997-2002), Former President of Ireland (1990-1997)

"When I talk to executives from pharmaceutical companies they tell me that they want to do more for neglected diseases, but they at least need to get credit for it. The Access to Medicine Index does exactly that."